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Introduction
Infection with Helicobacter pylori is recognized as a primary factor in the aetiology of gastric disease, and results in the excessive generation of prostaglandin (PGE 2 ) and nitric oxide (NO) triggered by disturbances in cyclooxygenase (COX). Nitric oxide synthase (NOS) isozyme systems are considered to be of major importance in defining the extent of gastric mucosal inflammatory involvement [1] [2] [3] [4] [5] [6] . Studies on the signalling events underlying the up-regulation of PGE 2 and NO generation indicate that H. pylori cell wall lipopolysaccharide (LPS), like that of other Gram-negative bacteria, is capable of triggering the stimulation of Toll-like receptor-4 (TLR-4), which then through a series of downstream effectors, causes the activation of transcriptional factors that exert control over NOS and COX-2 gene expression 2,7-9 . The engagement of TLR-4 by LPS, moreover, is known to elicit the activation of mitogen-activated protein kinase (MAPK) cascade, including extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 kinase, which in turn exert their control over transcription factor activation through phosphorylation [10] [11] [12] [13] . Indeed, we have recently shown that stimulation of gastric mucosal cells with H. pylori LPS elicits the activation of JNK, p38 and ERK and have linked the involvement of JNK/p38 in the transcription factor AP-1 activation, as well as provided evidence for the role of ERK activation in the regulation of factors linked to the induction of COX-2 and inducible NOS (iNOS) expression for the increase in PGE 2 and NO generation 9, 14 . Moreover, literature indicates that LPS-induced activation of MAPK cascade is also associated with epidermal growth factor receptor (EGFR) transactivation [15] [16] [17] . EGFR is a transmembrane glycosylated protein with intrinsic tyrosine kinase activity that controls a wide variety of cell functions that are of significance to mucosal defence and repair. These include processes such as cellular proliferation, differentiation, migration and modulation of apoptosis 18, 19 . Studies indicate that in addition to direct EGFR activation by its cognate EGF peptide ligand, transactivation of EGFR requires an extracellular matrix metalloproteinase (MMP)-mediated shedding of heparin-binding EGF-like growth factor (HB-EGF) and its subsequent binding to the receptor 19, 20 . Furthermore, the crosstalk between TLR4 and EGFR signalling systems has been linked to rapid changes in the extent of mucosal inflammation with bacterial invasion 21, 22 . In particular, there are strong indications that p38 MAPK activation plays an important role in MMP-2 and MMP-9 activation and that EGFR transactivation results in up-regulation in ERK MAPK pathway stimulation [23] [24] [25] [26] . Competing interests: none declared. Conflict of interests: none declared.
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EGFR transactivation assay
Measurement of EGFR transactivation was conducted with PhosphoDetect Elisa kit (Calbiochem).
The gastric mucosal cells from the control and various experimental conditions were washed twice with phosphate-buffered saline, treated with the receptor extraction buffer and centrifuged at 1500× g for 10 min at 4°C. The supernatant was then incubated at room temperature for 2 h with anti-EGFR antibody, followed by 30-minute incubation with protein A agarose and centrifugation
28
. After washing, the pellet was suspended in kinase reaction buffer, and 100 µL aliquots were used for EGFR phosphotyrosine assay following the manufacturer's instructions.
IκB kinase activity assay
To measure the inhibitory κB kinase-β (IKK-β) activity, we utilized the ELI-SA-based detection kit, K-LISA (Calbiochem). The GST-IκB-α50-amino acid peptide that includes the Ser 32 and Ser 36 of IκB-α phosphorylation sites was used as a substrate 27, 29 . The gastric mucosal cell cytosolic extracts were incubated with a glutathionecoated 96-well plate with GST-tagged IκB-α at room temperature for 30 min, and the phosphorylated GST-IκB-α substrate was detected using anti-phospho-IκB-α (Ser 32 
/Ser

36
) as first antibody, followed by horseradish peroxidase-conjugated secondary antibody. Following washing, the retained complex was probed with 3,3',5,5'-tetramethylbenzidine reagent for spectrophotometric quantification.
Immunoblot analysis
The gastric mucosal cells from the control and experimental treatments were collected by centrifugation and resuspended for 30 min in ice-cold lysis buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM EDTA, 1 mM sodium orthovanadate, 4 mM sodium pyrophosphate, 1 mM PMSF and 1 mM spectrum MMPinhibitor, GM6001 (Calbiochem), the cells were first preincubated for 30 min with the indicated dose of the agent or vehicle before the addition of the LPS. The viability of cell preparations before and during the experimentation, assessed by Trypan blue dye exclusion assay 6 , was greater than 97%.
iNOS activity assay
The activity of iNOS enzyme in gastric mucosal cells was measured by monitoring the conversion of L-
3 H] citrulline using NOS-detect kit (Stratagene). The gastric mucosal cells from the control and experimental treatments were homogenized in a sample buffer containing 10 mM EDTA and centrifuged. The aliquots of the resulting supernatant were incubated for 30 min at 25°C in the presence of 50 µCi/mL of L-[
3 H] arginine, 10 mM NAPDH, 5 µM tetrahydrobiopterin and 50 mM Tris-HCl buffer, pH 7.4, in a final volume of 250 µL. Following the addition of stop buffer and Dowex-50 W (Na + ) resin, the mixtures were transferred to spin cups, centrifuged and the formed L-[
3 H] citrulline contained in the flowthrough was quantified by scintillation counting 27 .
COX-2 activity assay
For measurements of COX-2 activity, the gastric mucosal cells from the control and various experimental treatments were settled by centrifugation, rinsed with phosphate-buffered saline and homogenized in 0.3 mL of cold sample buffer containing 0.1 M Tris-HCl, pH 7.8, and 1 mM EDTA, centrifuged at 12,000×g for 10 min at 4°C and the supernatant collected
27
. The COX-2 activity in 40 µL sample aliquots of the resulting supernatant was measured using COX activity assay kit (Cayman) in the absence and presence of COX-1 inhibition (SC-560), by monitoring the appearance of oxidized TMPD at 590 nm 14 . As gastric mucosal responses to H. pylori are reflected in MAPK activation 9, 14 , in this study we investigated the relationship between H. pylori LPS-induced MAPK activation and the processes associated with EGFR transactivation. Our results demonstrate that the LPS-induced p38 activation along with MMPs are of critical significance to EGFR transactivation that leads to up-regulation in the activation of ERK signalling cascade, amplification in iNOS and COX-2 induction and consequently to the excessive increase in gastric mucosal PGE 2 and NO generation.
Materials and methods
The protocol of this study has been approved by the relevant ethical committee related to our institution in which it was performed. Animal care was in accordance with the institution guidelines.
Cell incubation
The gastric mucosal cells, collected from dissected rats with a blunt spatula, were suspended in five volumes of ice-cold Dulbecco's modified (Gibco) eagle's minimal essential medium (DMEM), supplemented with fungizone (50 µg/mL), penicillin (50 U/ mL), streptomycin (50 µg/mL) and 10% foetal calf serum. After gentle trituration with a syringe, the dispersed cells were settled by centrifugation and resuspended in the medium at a concentration of 2 × 10 7 cells/ mL 27 . Cell aliquots (1 mL) were then transferred to DMEM in culture dishes and incubated under 95% O 2 -5% CO 2 atmosphere at 37°C for up to 8 h in the presence of 0-100 ng/mL of H. pylori LPS Competing interests: none declared. Conflict of interests: none declared.
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a substantial suppression of the LPSinduced ERK1/2 phosphorylation, while the extent of p38 phosphorylation remained unaffected ( Figure 2 ). This attests to the involvement of EGFR transactivation in the mediation of the LPS-induced ERK1/2 activation.
To gain further understanding of the mechanism of H. pylori LPSinduced EGFR transactivation, we next focused our attention on the pathways of EGFR activation. As EGFR activation in response to LPS while the expression of COX-2 protein was subject to suppression by the inhibitor of p38, SB202190. Further, following on recent literature evidence on the role of LPS in EGFR transactivation 16 , we assessed the MAPK requirement for H. pylori LPSinduced EGFR transactivation. For this, we examined the effect of EGFR kinase inhibitor, AG1478, on the LPSinduced phosphorylation of ERK1/2 and p38. The results of assays revealed that pretreatment of gastric mucosal cells with AG1478 leads to NaF), containing 1 µg/mL leupeptin and 1 µg/mL pepstatin
5
. Following brief sonication, the lysates were centrifuged at 12,000×g for 10 min, and the supernatants were collected and normalized with respect to protein concentration using BCA protein assay kit (Pierce). The samples, including those subjected to biotin switch procedure, were then resuspended in loading buffer, boiled for 5 min and subjected to SDS-PAGE using 40 µg protein/lane. The separated proteins were transferred onto nitrocellulose membranes, blocked for 1 h with 5% skim milk in Tris-buffered Tween (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween-20) and probed with specific antibodies directed against ERK1/2, phospho-ERK1/2, p38, phospho-p38, COX-2 and iNOS (Calbiochem), EGFR, phospho-EGFR (Tyr   1068   ) , IKK-β (EMD Millipore) and phospho-IKK-β (Cell Signalling). The anti-β actin was from Sigma.
Data analysis
All experiments were carried out using duplicate sampling, and the results are expressed as means ± SD. Analysis of variance and nonparametric Kruskal-Wallis tests were used to determine significance. Any difference detected was evaluated by means of post-hoc Bonferroni test, and the significance level was set at P < 0.05.
Results
Recently, we reported that gastric mucosal inflammatory responses to H. pylori infection, characterized by the excessive NO and PGE 2 generation, are primarily linked to the LPSinduced activation of MAPK
9
. Indeed, as illustrated in Figure 1 , incubation of rat gastric mucosal cells with H. pylori LPS leads to a significant induction in the level of iNOS and COX-2 proteins. Moreover, upon further examination, we found that the LPSinduced expression of iNOS protein exhibited susceptibility to inhibition by the ERK1/2 inhibitor, PD98059, , we employed Src kinase-specific inhibitor, PP2, and a broad-spectrum MMP inhibitor, GM6001, in the assessment of the LPS-induced gastric mucosal EGFR phosphorylation. The results of Western blot analysis revealed that while Src inhibitor, PP2, had no effect on the extent of H. pylori LPS-induced EGFR phosphorylation, a significant decrease in the EGFR phosphorylation was attained in the presence of MMP inhibitor, GM6001 (Figure 3) . Moreover, the LPS-induced EGFR phosphorylation was susceptible to inhibition by p38 MAPK inhibitor, SB202190. However, neither the MMP nor p38 inhibitor affected the EGFR phosphorylation induced by EGF. Furthermore, similar requirements for H. pylori LPS-induced gastric mucosal EGFR activation were also observed using EGRF protein tyrosine kinase activity assay ( Figure  4 ). As shown in Figure 4 , the LPS-induced EGFR activity was not affected by the inhibitors of Src and ERK1/2 kinases, but showed susceptibility to the inhibitors of p38 and MMP, the effect of which was additive. Collectively, these results indicate that EGFR transactivation by H. pylori LPS Figure 3 : Effect of Src, p38 and MMP inhibitors on H pylori LPS-induced EGFR transactivation in gastric mucosal cells. The cells, preincubated for 30 min with 30 µM PP2, 20 µM SB202190 (SB) or 100 µM GM6001 (GM), were treated with 100 ng/mL of LPS or 10 ng/mL EGFR and incubated for 10 min. Cell lysates were analysed by Western blotting for total and phosphorylated EGFR (a) and the relative density of pEGFR protein (b) is expressed a fold of control. Total EGFR was used as a loading control. The data represent the means ± SD of four experiments. *P < 0.05 compared with that of control. **P < 0.05 compared with that of LPS. occurs with the involvement of p38 MAPK and MMP and do not appear to require Src participation.
As gastric mucosal responses to H. pylori LPS associated with the activation of MAPK ERK through phosphorylation have been linked to the processes of IKK-β activation for the induction in NO and PGE 2 production 14 , we next examined the role of EGFR transactivation in the LPS-induced ERK and IKK-β activation. Western blot analysis of the LPS-induced ERK1/2 phosphorylation in the presence of EGFR inhibitor, AG1478, revealed a partial decrease in ERK1/2 phosphorylation, while the specific inhibitors of ERK1/2, PD98059 and RAF kinase, Raf-1 inhibitor, evoked nearly complete suppression in the ER1/2 phosphorylation ( Figure 5 ). Further, we found that the inhibitors of ERK1/2 and RAF kinase, PD9809 and Raf-1, exerted profound inhibitory effect on the LPS-induced activity of IKK-β, a key enzyme of NF-κB activation pathway ( Figure 6 ). A significant decrease in the LPS-induced up-regulation in gastric mucosal cell IKK-β activity was also attained in the presence of EGFR inhibitor, AG1478, p38 MAPK inhibitor, SB202190, and MMP inhibitor, GM6001, while the inhibitor of Src, PP2, neither affected the LPS-induced ERK1/2 phosphorylation ( Figure 5 ) nor the activity of IKK-β (Figure 6 ). These findings thus clearly point to the role of H. pylori LPS-induced EGFR transactivation in the amplification of ERK-mediated up-regulation in gastric mucosal IKK-β activity and subsequent induction of proinflammatory iNOS and COX-2 enzymes.
Consequently, to provide additional support as to the role of EGFR transactivation in H. pylori LPS-induced up-regulation in NO and PGE 2 generation, we assessed the activity of iNOS and COX-2 enzymes in the presence of inhibitors of EGFR kinase, ERK and p38 MAPK. The results revealed that the LPSelicited induction in the activity of iNOS and COX-2 enzymes was susceptible to suppression by EGFR inhibitor, AG1478, as well as by the inhibitor of ERK1/2, PD98059 (Figure 7) . The effect of p38 MAPK inhibitor, SB202190, was reflected mainly in the suppression COX-2 activity, whereas the inhibitor of Src, PP2, had no effect on either of the two enzymes. Moreover, preincubation with nitrosothiol reducing . The data on the signalling events underlying the up-regulation in NO and PGE 2 generation by LPS, moreover, point to the role of MAPK activation in the control of cognate transcription factors that exert control over iNOS and COX-2 gene expression 8, 10, 12, 30 . Along these lines, we have recently provided evidence for the involvement of H. pylori LPS-elicited activation of p38 and ERK MAPK in the regulation of factors linked to the induction of gastric mucosal NO and PGE 2 production 9, 14 . As recent literature evidence indicates that LPSinduced activation of MAPK cascade is also associated with EGFR transactivation [15] [16] [17] , in the present study we investigated the role of EGFR transactivation in H. pylori LPS-stimulated induction in gastric mucosal iNOS and COX-2 expression.
Our data demonstrate that EGFR transactivation in gastric mucosal cells exposed to stimulation with H. pylori LPS is dependent on p38 MAPK and MMP activation and does not involve nonreceptor tyrosine kinase, Src, participation. We further show that the LPS-induced EGFR transactivation results in the amplification of ERK activity, up-regulation in ERKmediated IKK-β activation and subsequent induction in the expression of iNOS and COX-2 enzymes. Indeed, we found that the LPS-induced EGFR phosphorylation as well as tyrosine kinase activity showed susceptibility to the inhibitors of p38 MAPK and MMP, SB202190 and GM6001, but not that of Src inhibitor, PP2. Furthermore, neither MMP nor p38 inhibitor affected the phosphorylation of EGFR induced by EGF, whereas blocking EGFR kinase activity with together, these data suggest that H. pylori LPS-induced p38 MAPK activation along with MMPs plays the major role in EGFR transactivation that leads to amplification in the ERK signalling cascade, and consequently to up-regulation in gastric mucosal NO and PGE 2 production. agent, ascorbate, elicited a marked decrease in the LPS-induced COX-2 activity, but had no discernible effect on the extent of iNOS activation. We also observed that the LPSelicited induction in the activity iNOS and COX-2 enzymes was susceptible to suppression by iNOS inhibitor, 1400W (Figure 7 ). Taken , and we have recently shown that suppression of H. pylori LPS-induced COX-2 S-nitrosylation by iNOS inhibition results in the inhibition of PGE2 generation 9 . These data and the finding that the LPS-induced up-regulation in the activity of IKK-β was also susceptible to suppression by the inhibitors of ERK as well as EGFR transactivation, provide strong indication as to the role of EGFR transactivation in the amplification of ERK signalling cascade associated with up-regulation in gastric mucosal PGE 2 and NO generation in response to H. pylori.
Conclusion
The data present in this report demonstrate the critical role of MAPK signalling cascade in the mediation of gastric mucosal inflammatory responses to H. pylori LPS that lead to an up-regulation in gastric mucosal NO and PGE 2 generation. The LPSinduced p38 MAPK activation along with MMPs plays a major role in EGFR transactivation that leads to amplification in ERK phosphorylation, up-regulation in ERK-mediated IKK-β activation and increase in NF-κB nuclear translocation for the induction of iNOS expression and NO generation. The rise in iNOS-dependent NO, in turn, leads to COX-2 activation through S-nitrosylation and excessive PGE 2 production (Figure 8) . Thus, the extent of EGFR transactivation elicited by H. pylori LPS may be of primary importance in defining the degree of gastric mucosal inflammatory involvement that could also be of significance to the development of gastric carcinoma.
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Indeed, assessment of the gastric mucosal activity of the iNOS and COX-2 enzymes revealed that the LPS-elicited induction in the activity of both enzymes was susceptible to suppression by EGFR kinase inhibitor, AG1478, as well as by ERK1/2 inhibitor, PD98059. The effect of p38 MAPK inhibitor, SB202190, was reflected mainly in the suppression of COX-2 activity, while Src inhibitor, PP2, had no effect on either of the two enzymes. Furthermore, we found that nitrosothiol reducing agent, ascorbate, caused a marked decrease in the LPS-induced up-regulation in gastric mucosal COX-2 activity, but had no discernible effect on the extent of iNOS activation. Moreover, induction in the extent of iNOS and COX-2 activation by the LPS was susceptible to suppression by iNOS inhibitor, 1400W. In this connection, it is pertinent to note that NO stimulation through iNOS induction has been growth factor; IKK-β, inhibitory κB kinase-β; iNOS, inducible nitric oxide synthase; JNK, Jun N-terminal kinase; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; MMP, matrix metalloproteinase; NO, nitric oxide; NOS, nitric oxide synthase; Figure 8 : Schematic representation of the proposed mechanism involved in H. pylori LPS-elicited EGFR transactivation leading to the excessive gastric mucosal NO and PGE 2 generation. Binding of the LPS to TLR4/MD4 initiates the activation of MAPKs and factors involved in the induction of COX-2 and iNOS expression. While JNK and p38 MAPKs promote the activation of factors (AP-1, CREB and C/EBP) implicated in the induction of COX-2 protein expression, activation of ERK MAPK leads to IKK-β-mediated activation of NF-κB for the induction in iNOS expression. Concomitantly, the LPS-activated p38 MAPK along with MMPs triggers the transactivation of EGFR that leads to the amplification in ERK phosphorylation, up-regulation in ERK-mediated IKK-β activation and the increase in NF-κB nuclear translocation for the enhanced induction in iNOS expression and NO generation. This leads to COX-2 activation through iNOS NOdependent S-nitrosylation and the excessive PGE 2 production. AP-1, activator protein-1; ATF-2, activating transcription factor-2; CREB, cAMP response element-binding protein; C/EBP, CCAAT/enhancer-binding protein; TLR4, Toll-like receptor 4.
